Pharma
Caris Life Sciences has commercially launched Caris Detect, a multi-cancer early detection (MCED) blood test that uses artificial intelligence (AI) and genomic sequencing to identify biological signals associated with cancer at earlier stages.
According to the company, the blood test combines ultra-deep whole genome sequencing, whole transcriptome sequencing, and AI to analyze deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and other molecular patterns from a blood sample. Caris said the approach provides broader biological coverage than tests that rely on more limited genomic data.
AI and genomic sequencing underpin the new test
Caris said Caris Detect is powered by its molecular profiling database of more than one million cases and over 50 billion molecular markers. The company said its AI models use this dataset to identify subtle biological signals associated with multiple cancer types, particularly during earlier stages of disease.
